Kaken Pharmaceutical
4521 · TSE
Public Market Listing
Live quotes, historical charts, and market capitalization for Kaken Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Seladelpar(Livdelzi) | Approved | PPAR-deltaSmall molecule | Cholestatic Liver Disease Primary Biliary Cholangitis |
| Phase 3 | TYK2Small molecule | PsoriasisSystemic Lupus Erythematosus |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (3)
November 2028 (2)
What to watch
What to watch
December 2028 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.